Exelixis Q1 2026: Strong Cabozantinib Sales, Zanzalintinib Hope

Exelixis starts 2026 strong with $611M in Q1 revenue, driven by cabozantinibs 8% U.S. sales growth and 12.5% global sales jump. Focusing on solid tumor oncology, they await FDA decision on zanzalintinib for third-line-plus colorectal cancer. Seven pivotal trials and new phase two studies are underway. Cabozantinibs market share leads in renal cell carcinoma and neuroendocrine tumors. Exelixis plans topline data from key kidney cancer trials this year and advances early assets. They reported $210.5M GAAP net income, held $1.4B cash, and bought back $430M in stock. Exelixis aims to balance cabozantinib growth, zanzalintinib momentum, and strategic investments for lasting value in oncology. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/033233b2910cc773